News & Articles

How scientists at Kato Pharmaceuticals have expanded from early-stage development to biopharmaceutical production of clinical drug products

These findings are the first evidence that a pre-emptive intervention during infancy could lead to a child falling below the threshold for a clinical diagnosis of autism

First dose delivered to patients in a multi-center U.S. clinical trial to evaluate novel gamma-delta T cell cancer therapy

Offering user-friendly, efficient specimen collection, the Combo Swab is expected to dramatically improve COVID-19 testing efficiency

Using Cytel’s expertise, the TOGETHER Trial simultaneously tests multiple repurposed therapies

Amulet device is the first minimally invasive option approved for left atrial appendage occlusion that does not require blood-thinning medication

Researchers announce the results of a study into thrombocytopenia and thromboembolic events following Covid-19 vaccination

Adults who have received a double vaccination are 47% less likely to have long COVID

Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cell model

Obtaining two vaccine doses remains the most effective way to ensure protection against the COVID-19 Delta variant

Fewer than one in 20 children with symptomatic COVID-19 experienced symptoms lasting longer than 4 weeks, and almost all children have fully recovered by 8 weeks

Patients with underlying heart problems are more than four times as likely to die from COVID-19

The fully automated CN-3000 and CN-6000 Systems bring mid- and high-volume coagulation testing to laboratories

Vaccine aims to combat numerous HIV strains, a key requirement of any vaccine to end the HIV/AIDs epidemic

Dr. Erik Tillman shares his virtual company’s quest to find an effective new life-changing treatment for non-alcoholic steatohepatitis

Researchers found that longer dosing intervals led to higher antibody levels and a higher proportion of ‘helper’ T cells

A new platform to simplify deep profiling of the human immune system

Discover the impact of the COVID-19 pandemic on a clinical research facility and the future of clinical trial recruitment

Partnership includes initial upfront payments and will potentially deliver recurring revenues for over 10 years

The authorization enables emergency use of Actemra/RoActemra for the treatment of COVID-19 in hospitalized adult and pediatric patients

VITROS Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies